Showing results (161-170 of 322) with videos related to

Sort By:
Pageof 33
Advances in Therapy|July 11, 2024
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2Claire N Harrison, Alessandro M Vannucchi, Christian Recher, et al.
Journal of Clinical Medicine|March 29, 2023
Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World ExperienceGiancarlo Castaman, Silvia Linari, Lisa Pieri, et al.
Annals of Hematology|October 8, 2021
Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world dataAndrew T Kuykendall, Libo Sun, John Mascarenhas, et al.
Blood Cells, Molecules & Diseases|March 14, 2007
The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasiaVittorio Rosti, Margherita Massa, Alessandro M Vannucchi, et al.
Blood|January 25, 2005
A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosisAlessandro M Vannucchi, Lucia Bianchi, Francesco Paoletti, et al.
Blood Advances|August 11, 2020
RAS/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic featuresGiacomo Coltro, Giada Rotunno, Lara Mannelli, et al.
Haematologica|November 17, 2018
EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysisAlessandro M Vannucchi, Peter A W Te Boekhorst, Claire N Harrison, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|December 28, 2021
Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional statusSilvia Aspite, Filippo Schepis, Davide Roccarina, et al.
Hematological Oncology|March 8, 2024
Texture analysis of 18F-FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvementElisabetta M Abenavoli, Flavia Linguanti, Matilde Anichini, et al.
American Journal of Hematology|December 3, 2025
A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative NeoplasmNiccolò Bartalucci, Danilo Tarantino, Giuseppe G Loscocco, et al.
Pageof 33